NCT02851420

Brief Summary

The detection of suspect lesions is based on the clinical examination of the oral cavity and pharyngolaryngeal endoscopy, but the examination to confirm the diagnosis is a pathology examination of the biopsy taken during the endoscopy. Taking the biopsy, however, can be difficult. On the one hand , it is an invasive procedure, and may engender complications, and on the other hand, certain modifications of the mucosa may be discrete, or not particularly specific or, on the contrary, disseminated or extremely widespread. Non-invasive tools to help the diagnosis could prove to be particularly interesting 1) to restrict the use of biopsies to patients in whom it is really necessary 2) and to identify the area where the biopsy should be done in cases of multiple lesions. In this context, spectroscopy could be a promising alternative. The investigator puts forward the hypothesis that cancerous and precancerous lesions of the mucosa of the upper airways and digestive tract present a characteristic spectrometric profile. Indeed, as malignant tumours are hypervascularized and as precancerous tumours show signs of angiogenesis, investigators expect that the reflectance of haemoglobin will be diminished in the specific wavelengths of 540 and 575 nm, corresponding to the principal wavelengths absorbed by haemoglobin. This pilot study will make it possible to construct an algorithm that could be used to classify lesions of the upper airways and digestive tract as either seemingly benign or cancerous.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
69

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 15, 2016

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

July 28, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 1, 2016

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 13, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 13, 2019

Completed
Last Updated

September 4, 2019

Status Verified

September 1, 2019

Enrollment Period

3.3 years

First QC Date

July 28, 2016

Last Update Submit

September 3, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Reflectance spectrum of haemoglobin

    Day one

Study Arms (2)

control

PLACEBO COMPARATOR
Other: spectroscopy

patient

EXPERIMENTAL
Other: spectroscopy

Interventions

controlpatient

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • patient - Patients consulting at the oto rhino laryngology department of Dijon for a functional symptom of the mouth, pharynx or larynx (pharyngeal discomfort, odynophagia, dysphagia, dysphonia, laryngeal dyspnoea) and in whom the clinical examination reveals a suspect lesion of the oral cavity, the pharynx or larynx and imposes an endoscopy procedure under general anaesthesia (unless it is a lesion of the tonsils or lingual tonsils)
  • Subjects who have provided consent
  • Subjects over 18 years old
  • volunteers:- Volunteers
  • Absence of risk factors cancerous oro-pharyngeal lesions, that is to say, non-smokers, alcohol consumption \< 1 glass per day.
  • Absence of functional oto rhino laryngology symptoms (dyspnoea, dysphagia, dysphonia, pain)
  • Subjects who have provided consent
  • Subjects over 18 years old

You may not qualify if:

  • patient :- Patients without national health insurance cover
  • Pregnant or breast-feeding women
  • Biopsies not feasible
  • because of difficulty of exposure of the tumour
  • tumour not accessible to the biopsy forceps,
  • complications during the procedure making it impossible to do the biopsies (difficulties with ventilation)
  • Spectrometry not feasible
  • If exposure is difficult, tumour not accessible to the spectrometry probe (for example, a hypopharyngeal tumour in a patient with limited mouth opening)
  • In cases of anaesthesia complications, such as difficulties with ventilation
  • volunteers:- Persons without national health insurance cover
  • Pregnant or breast-feeding women
  • Presence of risk factors: alcohol-smoking
  • Presence of oto rhino laryngology functional symptoms

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Dijon Bourgogne

Dijon, 21079, France

Location

MeSH Terms

Interventions

Spectrum Analysis

Intervention Hierarchy (Ancestors)

Chemistry Techniques, AnalyticalInvestigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 28, 2016

First Posted

August 1, 2016

Study Start

February 15, 2016

Primary Completion

June 13, 2019

Study Completion

June 13, 2019

Last Updated

September 4, 2019

Record last verified: 2019-09

Locations